- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Knowledge Graph Search feature is available on CiNii Labs
- 【Updated on June 30, 2025】Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
Current status of genomic testing and treatment for biliary tract cancer
-
- Sasaki Takashi
- Department of Hepato-Biliary-Pancreatic Medicine, Gastroenterology Center, Cancer Institute Hospital of Japanese Foundation for Cancer Research
-
- Ozaka Masato
- Department of Hepato-Biliary-Pancreatic Medicine, Gastroenterology Center, Cancer Institute Hospital of Japanese Foundation for Cancer Research
-
- Sasahira Naoki
- Department of Hepato-Biliary-Pancreatic Medicine, Gastroenterology Center, Cancer Institute Hospital of Japanese Foundation for Cancer Research
Bibliographic Information
- Other Title
-
- 胆道癌における遺伝子診断・治療の現況
Search this article
Description
<p>Drug therapy plays a major role in the treatment of advanced biliary tract cancer, but its efficacy and treatment option are limited. Therefore, further development is indispensable for improving the overall prognosis of this cancer. Precision medicine, which examines genetic alterations in cancer and treat it with molecular targeted agents, is a new treatment option which is particularly expected for biliary tract cancer. Recently, several FGFR inhibitors and IDH inhibitors showed good efficacies and tolerability for advanced intrahepatic cholangiocarcinoma. In Japan, a cancer multi-gene panel testing has been approved by public insurance, and it is expected that treatment based on genetic alteration will further develop in the field of biliary tract cancer. However, there are many issues that needed to be resolved in the near future, such as the time until the results of genomic testing are obtained, the way to gain a sufficient volume of sample in inoperable cases, the lack of effective therapeutic agents for genetic alterations, and the cost of genomic testing.</p>
Journal
-
- Tando
-
Tando 34 (4), 663-671, 2020-10-31
Japan Biliary Association
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1391130851443630976
-
- NII Article ID
- 130007932301
-
- ISSN
- 18836879
- 09140077
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- CiNii Articles
- Crossref
-
- Abstract License Flag
- Disallowed